Prognosis and survival of young men with metastatic prostate cancer: Insights from a tertiary cancer centre in India

Objectives: Prostate cancer is the second most prevalent cancer among men and increasingly affects younger individuals. These younger patients display distinct clinical and pathological profiles, with unclear prognostic outcomes. This study retrospectively analyses prostate cancer cases in men aged ≤55 years treated at Tata Memorial Hospital to understand the disease's characteristics and outcomes in this age group. Material and Methods: From 2012–2021, electronic medical records identified patients aged ≤55 years diagnosed with metastatic prostate cancer. Clinical and treatment data were extracted for analysis. Results: The cohort comprised 150 patients (median age: 52 years). Most cases (95%) were adenocarcinoma, while 4% had neuroendocrine differentiation, and 1% presented pure small cell carcinoma. High-grade disease (Gleason 4–5) was common (87%), with 91% having prostate-specific antigen (PSA) levels >20 ng/mL. Bone metastases were predominant (91%), and 73% had high-volume disease. Treatment involved surgical castration (62%) or medical castration (38%). Initial therapies included docetaxel (52%), abiraterone (11%), or androgen deprivation therapy (ADT) alone (29%). ADT alone was more common before 2019, when combination therapies were less utilised. With a median follow-up of 61.4 months, the median overall survival (mOS) was 47.1 months, while survival post-castration resistance was 20.1 months. The mOS for ADT compared to ADT plus docetaxel or abiraterone was 44.8 vs. 59.2 months ( p = 0.062) in patients with low volume disease, and 37.7 versus 49.6 months ( p = 0.563) in patients with high volume disease. This lack of statistical significance may be attributed to the high proportion (28.4%) of high-volume disease patients who received ADT alone. Poor prognostic factors included neuroendocrine differentiation, Gleason 5, high disease volume, and visceral metastases. Conclusion: Younger prostate cancer patients demonstrate more aggressive disease and worse outcomes compared to older cohorts. Prospective randomised trials are crucial to optimising management for this distinct population.

Authors

Institutions

Publication Details

Journal
South Asian Journal of Cancer
Published
2026-11-21
DOI
https://doi.org/10.25259/sajc_9_2025
Primary Topic
Prostate Cancer Treatment and Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Prognosis and survival of young men with metastatic prostate cancer: Insights from a tertiary cancer centre in India

Kunal Naishadh Jobanputra, Archi Agrawal, Amandeep M. Arora, Vanita Noronha et al.
South Asian Journal of Cancer
Prostate Cancer Treatment and Research
article

Prognosis and survival of young men with metastatic prostate cancer: Insights from a tertiary cancer centre in India

Kunal Naishadh Jobanputra, Archi Agrawal, Amandeep M. Arora, Vanita Noronha, Nandini Sharrel Menon, Gagan J. Prakash, Aparna N. Katdare, Priyamvada Maitre, Vedang Murthy, Atul Tiwari, Santosh G. Menon, Kumar Prabhash, Nilesh Pandurang Sable, Mahendra Pal, Amit Joshi, Ashok Singhal, Minit Shah, Palak Bhavesh Thakkar
article en

Abstract

Objectives: Prostate cancer is the second most prevalent cancer among men and increasingly affects younger individuals. These younger patients display distinct clinical and pathological profiles, with unclear prognostic outcomes. This study retrospectively analyses prostate cancer cases in men aged ≤55 years treated at Tata Memorial Hospital to understand the disease's characteristics and outcomes in this age group. Material and Methods: From 2012–2021, electronic medical records identified patients aged ≤55 years diagnosed with metastatic prostate cancer. Clinical and treatment data were extracted for analysis. Results: The cohort comprised 150 patients (median age: 52 years). Most cases (95%) were adenocarcinoma, while 4% had neuroendocrine differentiation, and 1% presented pure small cell carcinoma. High-grade disease (Gleason 4–5) was common (87%), with 91% having prostate-specific antigen (PSA) levels >20 ng/mL. Bone metastases were predominant (91%), and 73% had high-volume disease. Treatment involved surgical castration (62%) or medical castration (38%). Initial therapies included docetaxel (52%), abiraterone (11%), or androgen deprivation therapy (ADT) alone (29%). ADT alone was more common before 2019, when combination therapies were less utilised. With a median follow-up of 61.4 months, the median overall survival (mOS) was 47.1 months, while survival post-castration resistance was 20.1 months. The mOS for ADT compared to ADT plus docetaxel or abiraterone was 44.8 vs. 59.2 months ( p = 0.062) in patients with low volume disease, and 37.7 versus 49.6 months ( p = 0.563) in patients with high volume disease. This lack of statistical significance may be attributed to the high proportion (28.4%) of high-volume disease patients who received ADT alone. Poor prognostic factors included neuroendocrine differentiation, Gleason 5, high disease volume, and visceral metastases. Conclusion: Younger prostate cancer patients demonstrate more aggressive disease and worse outcomes compared to older cohorts. Prospective randomised trials are crucial to optimising management for this distinct population.

South Asian Journal of CancerVol. 0
Tata Memorial Hospital (IN), Advanced Centre for Treatment, Research and Education in Cancer (IN)
Prostate Cancer Treatment and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon